Recombinant Human TSH Increases Uptake and Effective Half-life of Radioiodine in Thyroid Hormone Secreting Metastases of Follicular Thyroid Cancer

被引:4
|
作者
Schneider, C. [1 ]
Dietlein, M. [1 ]
Eschner, W. [2 ]
Schmidt, M. [1 ]
Kahraman, D. [1 ]
Kobe, C. [1 ]
机构
[1] Univ Hosp Cologne, Dept Nucl Med, D-50937 Cologne, Germany
[2] Univ Cologne, Dept Nucl Med, D-50931 Cologne, Germany
关键词
follicular thyroid cancer; thyroid hormone secreting metastases; radioiodine therapy; rhTSH; CARCINOMA; HYPERTHYROIDISM; RECOMMENDATIONS; DIAGNOSIS;
D O I
10.1055/s-0031-1299710
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Follicular thyroid cancer with thyroid hormone secreting metastases is an extremely rare condition, with only a few cases reported world-wide. We here present the case of a 64-year-old female patient affected by follicular thyroid cancer with extensive thyroid hormone secreting metastases leading to TSH-suppression. We have also summarized the relevant diagnostic and therapeutic approaches and describe, for the first time, the effects of rhTSH-application in this rare tumor entity. In this patient, we found that rhTSH increased I-131-uptake into the thyroid hormone secreting metastases and prolonged the effective half-life of I-131. These effects of rhTSH should be considered when fixed activities of I-131 are prescribed.
引用
收藏
页码:160 / 163
页数:4
相关论文
共 50 条
  • [41] Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: A meta-analysis
    Tu, Jian
    Wang, Siwen
    Huo, Zijun
    Lin, Ying
    Li, Xiaoxi
    Wang, Shenming
    RADIOTHERAPY AND ONCOLOGY, 2014, 110 (01) : 25 - 30
  • [42] Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study
    Taieb, D.
    Sebag, F.
    Cherenko, M.
    Baumstarck-Barrau, K.
    Fortanier, C.
    Farman-Ara, B.
    De Micco, C.
    Vaillant, J.
    Thomas, S.
    Conte-Devolx, B.
    Loundou, A.
    Auquier, P.
    Henry, J. F.
    Mundler, O.
    CLINICAL ENDOCRINOLOGY, 2009, 71 (01) : 115 - 123
  • [43] Redifferentiation Therapy with Rosiglitazone in a case of Differentiated Thyroid Cancer with Pulmonary Metastases and Absence of Radioiodine Uptake
    Elola, M.
    Yoldi, A.
    Emparanza, J. I.
    Matteucci, T.
    Bilbao, I.
    Goena, M.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR, 2011, 30 (04): : 241 - 243
  • [44] Effects of recombinant human thyroid stimulating hormone on 131I therapy for the treatment of differentiated thyroid cancer
    Guo, Yiling
    Zhang, Yingnan
    Chen, Zuowei
    Xin, Zhenfu
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 9 (05) : 1847 - 1850
  • [45] Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer
    Pacini, Furio
    Castagna, Maria Grazia
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 22 (06) : 1009 - 1021
  • [46] Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH
    Pitoia, Fabian
    Abelleira, Erika
    Cross, Graciela
    ENDOCRINE, 2017, 55 (01) : 209 - 217
  • [47] Radioactive iodine uptake in hyperthyroid cats after administration of recombinant human thyroid stimulating hormone
    Oberstadt, Amy E.
    Nelson, Nathan C.
    Claude, Andrew K.
    Refsal, Kent R.
    Scott-Moncrieff, J. Catharine
    Petroff, Brian K.
    Langlois, Daniel K.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2018, 32 (06): : 1891 - 1896
  • [48] Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients
    Barbara Jarząb
    Daria Handkiewicz-Junak
    Józef Roskosz
    Zbigniew Puch
    Zbigniew Wygoda
    Aleksandra Kukulska
    Beata Jurecka-Lubieniecka
    Kornelia Hasse-Lazar
    Maria Turska
    Aleksander Zajusz
    European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30 : 1077 - 1086
  • [49] Cytotoxic and genotoxic effects of 131I and 60Co in follicular thyroid cancer cell (WRO) with and without recombinant human thyroid-stimulating hormone treatment
    Silva Valgode, Flavia Gomes
    da Silva, Marcia Augusta
    Vieira, Daniel Perez
    Carvalho Pinto Ribela, Maria Teresa
    Bartolini, Paolo
    Okazaki, Kayo
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2017, 58 (06) : 451 - 461
  • [50] Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT-Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer
    Plyku, Donika
    Hobbs, Robert F.
    Huang, Kevin
    Atkins, Frank
    Garcia, Carlos
    Sgouros, George
    Van Nostrand, Douglas
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (07) : 1146 - 1154